Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer
Open accessAbstract
Carbohydrate antigen (CA) 19-9 is the only diagnostic marker used in pancreatic cancer despite its limitations. Here, we aimed to identify the diagnostic role of CEMIP (also called KIAA1199) combined with CA 19-9 in patients with pancreatic cancer. A retrospective analysis of prospectively collected patient samples was performed to determine the benefit of diagnostic markers in the diagnosis of pancreatic cancer. We investigated CEMIP and CA 19-9 levels in 324 patients with pancreatic cancer and 49 normal controls using serum enzyme-linked immunosorbent assay. Median CA 19-9 and CEMIP levels were 410.5 U/ml (40.8–3342.5) and 0.67 ng/ml (0.40–1.08), respectively, in patients with pancreatic cancer. The AUROC for CA 19-9 and CEMIP were 0.847 (95% confidence interval [CI]: 0.806–0.888) and 0.760 (95% CI: 0.689–0.831), respectively. Combination of CA 19-9 with CEMIP showed markedly improved AUROC over CA 19-9 alone in pancreatic cancer diagnosis (0.94 vs. 0.89; P < 0.0001). CEMIP showed a diagnostic yield of 86.1% (68/79) in CA 19-9 negative pancreatic cancer. Combined use with CEMIP showed significantly improved diagnostic value compared with CA 19-9 alone in pancreatic cancer. Especially, CEMIP may be a complementary marker in pancreatic cancer patients with normal CA 19-9 levels.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A combination of CA19-9 and CEMIP gave a higher area under the ROC curve than CA19-9 alone, 0.94 versus 0.89.
“Lee and colleagues78 reported an improved area under receiver operating characteristic curve (AUC) using a combination of CA19–9 and cell migration-inducing hyaluronan binding protein (CEMIP; a protein involved in the degradation of hyaluronan) compared with using CA19–9 alone (AUC=0·94 vs 0·89).”
From Early detection of pancreatic cancer (2020) · cites this paper as [78]
CEMIP correctly identified 68 of 79 pancreatic ductal adenocarcinoma patients whose CA19-9 was below 37 U/mL.
“Importantly, CEMIP correctly diagnosed 68 of 79 patients with pancreatic ductal adenocarcinoma whose CA19–9 concentrations were in the normal range (below 37 U/mL).”
From Early detection of pancreatic cancer (2020) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J.-W., Kamel, I., Nio, Y., Schulick, R. S., Bassi, C., Kluijt, I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303108 · Cited by 784 · see citing works
Early Detection of Sporadic Pancreatic Cancer: Summative Review
Chari, S. T., Kelly, K., Hollingsworth, M. A., Thayer, S. P., Ahlquist, D. A., Andersen, D. K., Batra, S. K., Brentnall, T. A., Canto, M., Cleeter, D. F., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000368 · Cited by 295 · see citing works
Kanda, M., Sadakari, Y., Borges, M., Topazian, M., Farrell, J., Syngal, S., Lee, J., Kamel, I., Lennon, A. M., Knight, S., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.11.016 · Cited by 181 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Early detection of pancreatic cancer
Pereira, S. P., Oldfield, L., Ney, A., Hart, P. A., Keane, M. G., Pandol, S. J., Li, D., Greenhalf, W., Jeon, C. Y., Koay, E. J., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30416-9 · Cited by 482 · see citing works
- Authors
- Lee, H. S., Jang, C. Y., Kim, S. A., Park, S. B., Jung, D. E., Kim, B. O., Kim, H. Y., Chung, M. J., Park, J. Y., Bang, S., Park, S. W., & Song, S. Y.
- Affiliations
- Yonsei University (KR)
- Corresponding author
- Song, Si Young
- ORCID
- Venue
- Scientific Reports
- Published
- 2018-02-21
- Volume
- 8
- Issue
- 1
- Pages
- 3383-3383
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5821821
- OpenAlex
- W2796588262
- Cited by
- 44
- References
- 3
- Citations by year
- 2025: 4 · 2024: 4 · 2023: 4 · 2022: 8 · 2021: 11 · 2020: 5 · 2019: 5 · 2018: 2 · 2017: 1
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Funders
- National Research Foundation
- Yonsei University (HI14C1324)
- Korea Health Industry Development Institute (HI14C1324)
- National Research Foundation of Korea (HI14C1324)
- Ministry of Science and ICT, South Korea
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Keywords
- pancreatic cancer, CEMIP, KIAA1199, CA19-9, serum tumor markers, diagnostic accuracy, early diagnosis
- MeSH terms
- Carcinoembryonic Antigen, Female, Humans, Hyaluronoglucosaminidase, Male, Middle Aged, Neoplasm Staging, Pancreatic Neoplasms, Prospective Studies, Proteins, Retrospective Studies, Biomarkers, Tumor, CA-19-9 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
